Texas Capital Bancshares, Inc. Appoints Ranjana B. Clark to Board of Directors DALLAS, April 22, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the appointment of Ranjana B. Clark to its Board of Directors, effective April 15, 2025. Clark will serve as a member of the Audit and Technology Committees. Clark has over 35 years of executive experience in the financial services and technology industries, with previous leadership roles spanning payments, marketing, strategy and business operations. Most recently, sh...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, April 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” Th...
Texas Capital Bancshares, Inc. Announces First Quarter 2025 Results First quarter 2025 net income of $47.0 million and net income available to common stockholders of $42.7 million, or $0.92 per diluted share Strong balance sheet growth with total deposits increasing 9% and total loans growing 7% year-over-year Book Value and Tangible Book Value(1) per share both increasing 11% year-over-year, reaching record levels Capital ratios continue to be strong, including 11.6% CET1 and 15.6% Total Capital DALLAS, April 17, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI),...
Texas Capital President & Chief Executive Officer Rob C. Holmes Now Serves as Chairman of the Board DALLAS, April 15, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that President & Chief Executive Officer Rob C. Holmes was confirmed as Chairman of the Board of Directors at the conclusion of TCBI’s 2025 Annual Meeting of Stockholders. Holmes, who has served as President & Chief Executive Officer and a Director of the Board since 2021, was to this position by the Board of Directors in January 2025. Bob Stalling...
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above ...
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit (“RSU”) awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...
Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Results DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2025 before market on Thursday, April 17, 2025. Executive management will host a conference call and webcast to discuss first quarter 2025 operating results on Thursday, April 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to ...
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endoc...
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee; and granted an aggregate of 40,775 restricted stock unit (“RSU”) awards to sixteen new non-executive employees and 52,000 to one new executive employee; ...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeline in 2025 Strong Financial Position with $1.4B Cash with Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.